Jove
Visualize
Contact Us

Related Experiment Videos

Nadia Karina Aguilar Hinojosa1, Evelyn Itzamara Figueroa Saavedra2

  • 1Adscrita al servicio de Alergología.

Revista Alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)
|November 7, 2023
PubMed
Summary
This summary is machine-generated.

A rapid desensitization protocol for deferasirox (an iron chelator) can be effective for patients with hemochromatosis experiencing adverse reactions. This approach offers a therapeutic option when other treatments fail.

Keywords:
AllergyDeferasiroxDesensitizationHemochromatosisalergiadesensibilizaciónhemocromatosis

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real word effectiveness of benralizumab in mexican patients with severe eosinophilic asthma: Responders and super-responders.

Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)·2026
Same author

Severe Asthma Patients' Characteristics in Mexico Versus International Severe Asthma Registry (ISAR) Global.

Current allergy and asthma reports·2026
Same author

[Needs, limitations and opportunities to create a center of excellence for severe asthma care in the public healthcare system in Mexico].

Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)·2025
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Pharmacology
  • Hematology
  • Immunology

Background:

  • Deferasirox is a key iron chelator for treating iron overload conditions like hemochromatosis.
  • Adverse reactions to deferasirox affect up to 28% of patients.
  • Alternative therapeutic options are limited for patients with severe iron overload and drug intolerance.